PL377591A1 - Stabilized exendin-4 compounds - Google Patents

Stabilized exendin-4 compounds

Info

Publication number
PL377591A1
PL377591A1 PL377591A PL37759103A PL377591A1 PL 377591 A1 PL377591 A1 PL 377591A1 PL 377591 A PL377591 A PL 377591A PL 37759103 A PL37759103 A PL 37759103A PL 377591 A1 PL377591 A1 PL 377591A1
Authority
PL
Poland
Prior art keywords
compounds
stabilized exendin
exendin
stabilized
Prior art date
Application number
PL377591A
Other languages
Polish (pl)
Inventor
Kirsten Ebbehoej
Trine Jepsen
Carsten Boye Knudsen
Bjarne Due Larsen
David Knott
Original Assignee
Zealand Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma A/S filed Critical Zealand Pharma A/S
Publication of PL377591A1 publication Critical patent/PL377591A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL377591A 2002-10-02 2003-10-02 Stabilized exendin-4 compounds PL377591A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41562602P 2002-10-02 2002-10-02

Publications (1)

Publication Number Publication Date
PL377591A1 true PL377591A1 (en) 2006-02-06

Family

ID=32107880

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377591A PL377591A1 (en) 2002-10-02 2003-10-02 Stabilized exendin-4 compounds

Country Status (13)

Country Link
US (2) US7544657B2 (en)
EP (1) EP1546200A2 (en)
JP (1) JP2006517908A (en)
KR (1) KR20050083713A (en)
AU (2) AU2003268621B2 (en)
BR (1) BR0314996A (en)
CA (1) CA2500295A1 (en)
MX (1) MXPA05003335A (en)
NO (1) NO20051585L (en)
PL (1) PL377591A1 (en)
RU (1) RU2376314C2 (en)
WO (1) WO2004035623A2 (en)
ZA (1) ZA200502571B (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
NZ542371A (en) * 2003-03-19 2008-10-31 Universitatsspital Basel Radiolabeled conjugates based on substance P and the uses thereof
DE102004043153B4 (en) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Invention relating to GLP-1 and exendin
DE102004058306A1 (en) * 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Process for the preparation of carboxy-terminally amidated peptides
DE102005046113A1 (en) 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Preparation of C-amidated peptides, useful as pharmaceuticals, by reaction between precursor peptides in presence of enzyme with activity of trypsin, also new reaction products
EP1965828A2 (en) * 2005-12-02 2008-09-10 Nastech Pharmaceutical Company Inc. Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
WO2007067964A2 (en) * 2005-12-08 2007-06-14 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
WO2008116294A1 (en) * 2007-03-23 2008-10-02 Matregen Corp. Exendin analogs
JP2009019027A (en) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin secretion peptide derivative in which amino acid of amino terminal is varied
NZ586590A (en) 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
BRPI0907119A2 (en) * 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Insulin derivatives having an extremely delayed time action profile
PL2349324T3 (en) 2008-10-17 2018-02-28 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
DE102009038210A1 (en) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
DE102008051834A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
US20120232002A1 (en) * 2009-07-06 2012-09-13 Sanofi-Aventis Deutschland Gmbh Slow-acting insulin preparations
RU2573995C2 (en) * 2009-11-13 2016-01-27 Санофи-Авентис Дойчланд Гмбх Pharmaceutical composition containing glp-1 agonist and methionine
ES2534191T3 (en) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
DE102010011919A1 (en) 2010-03-18 2011-09-22 Sanofi-Aventis Deutschland Gmbh Liquid composition, useful for treating e.g. type II diabetes mellitus, and/or obesity, comprises a glucagon-like peptide-1 agonist and/or its salt e.g. exendin-4, optionally an adjuvant and methionine
US9089538B2 (en) 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
CN101891823B (en) * 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 Exendin-4 and analog fusion protein thereof
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP3028720A1 (en) 2010-09-28 2016-06-08 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
CN102532301B (en) * 2010-12-31 2014-09-03 上海医药工业研究院 Novel Exendin-4 analogues and preparation method thereof
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
US20140221282A1 (en) 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Long duration dual hormone conjugates
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
PL2750699T3 (en) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN102309453A (en) * 2011-09-27 2012-01-11 四川大学 Exenatide multivesicular liposome and preparation method thereof
WO2013050378A1 (en) 2011-10-04 2013-04-11 Sanofi-Aventis Deutschland Gmbh Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
PL2763690T3 (en) 2011-10-04 2016-04-29 Sanofi Aventis Deutschland Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
CA2853884A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
AU2013276610A1 (en) * 2012-06-14 2015-01-15 Sanofi Exendin-4 peptide analogues
MX356957B (en) 2012-07-23 2018-06-20 Zealand Pharma As Glucagon analogues.
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
UA116553C2 (en) 2012-12-21 2018-04-10 Санофі Functionalized exendin-4 derivatives
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2014147129A1 (en) * 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
SG11201506804VA (en) * 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of hydantoin containing peptide products
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TWI666220B (en) 2013-10-17 2019-07-21 丹麥商西蘭製藥公司 Acylated glucagon analogues
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CN105829339B (en) 2013-11-06 2021-03-12 西兰制药公司 glucagon-GLP-1-GIP triple agonist compounds
CN103613655B (en) * 2013-11-20 2015-05-13 陕西东大生化科技有限责任公司 Method for low-cost purification of exenatide
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3091965A1 (en) 2014-01-09 2016-11-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
RU2016132340A (en) 2014-01-09 2018-02-14 Санофи STABILIZED PHARMACEUTICAL COMPOSITIONS BASED ON INSULIN ASPART
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (en) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Peptide for medical treatment of pancreatic diabetes of 2nd type and its complications
TWI705973B (en) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Gip agonist compounds and methods
PE20171622A1 (en) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
TWI707867B (en) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 Acylated glucagon analogue
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
SG11201807832VA (en) 2016-03-16 2018-10-30 Prolynx Llc Extended release conjugates of exenatide analogs
AR110300A1 (en) 2016-12-02 2019-03-13 Sanofi Sa COMPOUNDS AS TRIGONAL PEPTIDE AGONISTS OF GLP1 / GLUCAGÓN / GIP RECEPTORS
AR110301A1 (en) 2016-12-02 2019-03-13 Sanofi Sa COMPOUNDS AS GLP1 / GLUCAGÓN / GIP RECEPTING AGENISTS
SG10201911851VA (en) 2016-12-09 2020-02-27 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
KR20200142032A (en) 2018-04-10 2020-12-21 사노피-아벤티스 도이칠란트 게엠베하 Synthesis of lixisenatide using capping
CA3096493A1 (en) * 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
UY38249A (en) 2018-05-30 2019-12-31 Sanofi Sa CONJUGATED PRODUCTS INCLUDING A TRIPLE GLP-1 / GLUCAGON / GIP RECEPTOR AGONIST, A CONNECTOR AND HYALURONIC ACID
CA3174635A1 (en) 2020-03-06 2021-09-10 Sanofi Peptides as selective gip receptor agonists
WO2022197819A1 (en) * 2021-03-17 2022-09-22 The Trustees Of Princeton University Sunscreens derived from kynurenines and other uv-absorbing oxidized amino acids bound to peptides or polymers
CN115521368B (en) * 2021-06-25 2024-08-23 江苏鸿永医药技术有限公司 Exendin-4 derivatives
WO2023031455A1 (en) 2021-09-06 2023-03-09 Sanofi Sa New peptides as potent and selective gip receptor agonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE69024953T3 (en) 1989-05-04 2005-01-27 Southern Research Institute, Birmingham encapsulation
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36392D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
DK39892D0 (en) 1992-03-25 1992-03-25 Bernard Thorens PEPTIDE
US5846747A (en) 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CA2474701C (en) 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
JP2000516912A (en) * 1996-06-05 2000-12-19 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Exendin analogs, methods for their preparation and formulations containing them
DE19637230A1 (en) * 1996-09-13 1998-03-19 Boehringer Mannheim Gmbh Truncated versions of exendin peptide(s) for treating diabetes
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
ATE417622T1 (en) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc REGULATION OF GASTROINTESTINAL MOBILITY
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
DE69831673C5 (en) 1997-01-07 2015-01-22 Amylin Pharmaceuticals, Llc USE OF EXEDINES AND THEIR ANTAGONISTS TO REDUCE FOOD CONSUMPTION
EP0981611A1 (en) 1997-02-05 2000-03-01 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
DE69838791T3 (en) 1997-08-08 2011-06-22 Amylin Pharmaceuticals, Inc., Calif. NEW EXENDINAGONIST CONNECTIONS
DK1032587T4 (en) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc New exendin agonist compounds
JP2003522721A (en) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド New exendin agonist compounds
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
ATE366115T1 (en) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1
JP2003522099A (en) * 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ GLP-1 derivative of GLP-1 having a delayed action profile and exendin
WO1999046283A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE69918070T2 (en) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilized, aqueous glucagon solutions containing detergents
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
EP1175443A1 (en) * 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels

Also Published As

Publication number Publication date
US20060194719A1 (en) 2006-08-31
WO2004035623A3 (en) 2004-06-03
WO2004035623A2 (en) 2004-04-29
EP1546200A2 (en) 2005-06-29
JP2006517908A (en) 2006-08-03
RU2376314C2 (en) 2009-12-20
BR0314996A (en) 2005-08-09
CA2500295A1 (en) 2004-04-29
AU2003268621B2 (en) 2009-01-15
US7544657B2 (en) 2009-06-09
AU2003268621A1 (en) 2004-05-04
RU2005113291A (en) 2006-01-20
ZA200502571B (en) 2006-02-22
MXPA05003335A (en) 2005-07-05
NO20051585L (en) 2005-06-20
KR20050083713A (en) 2005-08-26
US20090208565A1 (en) 2009-08-20
AU2009201477A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
PL377591A1 (en) Stabilized exendin-4 compounds
EP1558585A4 (en) Neurologically-active compounds
GB0222493D0 (en) Compounds
GB0209022D0 (en) Compounds
PL372622A1 (en) Oxo-azabicyclic compounds
GB0200283D0 (en) Compounds
AU2003216859A8 (en) Amidoacetonitrile compounds
GB0210762D0 (en) Compounds
GB0207323D0 (en) Compounds
GB0211418D0 (en) Compounds
GB0203778D0 (en) Compounds
GB0212399D0 (en) Compounds
GB0216985D0 (en) Compounds
GB0216233D0 (en) Compounds
GB0213011D0 (en) Compounds
GB0209244D0 (en) Compounds
AU2003275480A8 (en) Compounds
GB0203811D0 (en) Compounds
GB0206981D0 (en) Compounds
GB0225882D0 (en) Compounds
GB0207270D0 (en) Compounds
GB0203438D0 (en) Compounds
GB0203776D0 (en) Compounds
GB0202026D0 (en) Compounds
GB0203806D0 (en) Compounds

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)